pSivida Corp. (PSDV) ,,,,, un GIOIELLO !!! (1 Viewer)
- Creatore Discussione acqua+
- Data di Inizio
guly
Forumer storico
per fortnu che pfizer non era piu' interessata al settore OFTALMICO.che buffoni quelli della nicox.veramente dequalificante per garufi e co.al livello di J BIANCO.
Netzach
Forumer storico
furo
Forumer attivo
pSivida Announces Iluvien(R) Receives FDA Priority Review for Treatment of Diabetic Macular Edema
WATERTOWN, Mass., Aug 31, 2010 (BUSINESS WIRE) -- pSivida Corp. /quotes/comstock/15*!psdv/quotes/nls/psdv (PSDV 3.26, -0.05, -1.51%) (ASX
VA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences /quotes/comstock/15*!alim/quotes/nls/alim (ALIM 8.10, -0.07, -0.86%) has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).
FDA Priority Review status is given to therapies that offer major advances in treatment, or provide a treatment where no adequate therapy exists. This status reduces the review time goal from 10 months to six months.
Dr. Paul Ashton, President and CEO of pSivida said, "With priority review a response from the FDA regarding Iluvien could be received in the fourth quarter of this year. Approval of Iluvien would trigger a $25 million milestone payment to pSivida from Alimera. Under the license agreement pSivida is also to receive 20 percent of net profits on sales by Alimera."
The news regarding priority review follows the submission last month of the Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom. Applications have also been submitted to regulatory agencies in Austria, France, Germany, Italy, Portugal and Spain. Filing in Canada is expected to take place in September. pSivida has joint ownership and reference rights to these regulatory filings.
pSivida continues to work to develop new products for the sustained release of drugs and proteins based on its existing and new technologies. Additionally, Pfizer and pSivida are collaborating to develop ophthalmic products based on pSivida technology. While the Company remains primarily focused in ophthalmology, pSivida is exploring other therapeutic areas.
WATERTOWN, Mass., Aug 31, 2010 (BUSINESS WIRE) -- pSivida Corp. /quotes/comstock/15*!psdv/quotes/nls/psdv (PSDV 3.26, -0.05, -1.51%) (ASX
VA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences /quotes/comstock/15*!alim/quotes/nls/alim (ALIM 8.10, -0.07, -0.86%) has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME). FDA Priority Review status is given to therapies that offer major advances in treatment, or provide a treatment where no adequate therapy exists. This status reduces the review time goal from 10 months to six months.
Dr. Paul Ashton, President and CEO of pSivida said, "With priority review a response from the FDA regarding Iluvien could be received in the fourth quarter of this year. Approval of Iluvien would trigger a $25 million milestone payment to pSivida from Alimera. Under the license agreement pSivida is also to receive 20 percent of net profits on sales by Alimera."
The news regarding priority review follows the submission last month of the Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom. Applications have also been submitted to regulatory agencies in Austria, France, Germany, Italy, Portugal and Spain. Filing in Canada is expected to take place in September. pSivida has joint ownership and reference rights to these regulatory filings.
pSivida continues to work to develop new products for the sustained release of drugs and proteins based on its existing and new technologies. Additionally, Pfizer and pSivida are collaborating to develop ophthalmic products based on pSivida technology. While the Company remains primarily focused in ophthalmology, pSivida is exploring other therapeutic areas.
Netzach
Forumer storico
doctor NO
NO nel DNA
o confusione totale nell'interpretare???????????
Ehi genio guardati il grafico di PSDV pSivida Corp.: NASDAQSDV quotes & news - Google Finance massimi a 30€ e poi crollo sui 3€!!!!!!!!!!!!!!! non dici niente non chiedi la testa del CEO
semplice sei entrato a questi prezzi e ti sta bene cosi?????????????? ma cosa diresti se le avessi comprate a 30€??????????????? osserva bene buona parte delle biotech soggette a news e poi impara !!!!!!!!!!!!!!! se passi allo scoglio ti faccio un corso accellerato e ti stringo anche la mano in segno di pace
Mistificazione della realtà ...
Ehi genio guardati il grafico di PSDV pSivida Corp.: NASDAQ
SDV quotes & news - Google Finance massimi a 30€ e poi crollo sui 3€!!!!!!!!!!!!!!! non dici niente non chiedi la testa del CEO semplice sei entrato a questi prezzi e ti sta bene cosi?????????????? ma cosa diresti se le avessi comprate a 30€??????????????? osserva bene buona parte delle biotech soggette a news e poi impara !!!!!!!!!!!!!!! se passi allo scoglio ti faccio un corso accellerato e ti stringo anche la mano in segno di pace